39 results about "Metoprolol Tartrate" patented technology

The invention provides a Metoprolol Tartaric Acid and Felodipine slow-release double-layer tablet and its preparation method. The slow-release double-layer tablet comprises a Metoprolol Tartaric Acid slow-release layer containing, by weight, 50 parts of Metoprolol Tartaric Acid, 100-150 parts of an ethyl cellulose powder, 24-30 parts of ethyl cellulose in the form of an ethyl cellulose aqueous suspension and 130-230 parts of hydroxypropyl methyl cellulose; and a Felodipine slow-release layer containing 5 parts of Felodipine and 60 parts of hydroxypropyl methyl cellulose. By adjusting the ingredients and their ratio in the Metoprolol Tartaric Acid slow-release layer and the Felodipine slow-release layer, the release speeds of medicament layers can cooperate with each other and the slow-release effect is more reliable, thus reaching a good curative effect; in addition, it is ensured that the medicament layers can be smoothly compacted to form a double-layer tablet, and the hidden trouble of damaged coating particles can be avoided. The preparation method provided by the invention mainly employs the double-layer tablet compacting technology with simple equipment, can save cost and is suitable for industrial production.

The invention discloses a metoprolol tartrate extended release compound which comprises a. a hollow pill core; b. an active medicine layer containing metoprolol or medicine salt of the metoprolol and at least a bond, and the layer is positioned on the surface of the hollow pill core; c. a release coat layer containing acrylic acid resin NE30D and French chalks, and the release coat layer is positioned outside the active medicine layer. The invention also discloses a method of preparing the medicine compound.

The invention belongs to the field of pharmaceutical medicine, and relates to an extrusion 3D printing coating type sustained-release preparation and a preparation method thereof. The coated sustained-release preparation of the present invention is based on a mixture of gelatin, glycerin and water, adding drugs or HPMC to obtain an inner core or coating, and then extruding 3D printing in combination with model slices and printing parameters to obtain the target coating sustained-release preparations. The formula has good printability, taking into account "smooth extrusion" and "rapid deposition". Compared with the existing slow-release printing materials, the water content of the system is reduced, and the strength and elasticity of the sample are increased. The optimized coating model structure can solve the problems existing in the existing extrusion 3D printing sustained-release preparations, including: low drug loading, obvious early burst release and unsatisfactory 24h sustained-release behavior. The present invention is further represented by diclofenac sodium, aminophylline, metoprolol tartrate and acetylsalicylic acid, disclosing the application effect of coated sustained-release preparations, proving that by adjusting the drugs and models, the individualization of various drugs can be realized treat.

The invention provides a metoprolol tartrate sustained-release tablet and a preparation method thereof. The tablet is composed of the components of, by weight: 30-50% of metoprolol tartrate, 15-30% of a sustained-release framework material, 0.35-10.0% of a lubricant, 10.0-30.0% of an adhesive, 0.5-5.0% of a film coating premix, and 10.0-30.0% of purified water. Compared with prior art, the tablet and the method provided by the invention have the advantages of simple preparation method, low production cost, suitability for industrialized productions, no greasy and sticky phenomenon during a production process, and smooth release curve. With the tablet, a sudden release phenomenon of a first time period is prevented, and a phenomenon of unqualified release speed at a first time period is also prevented.

The invention provides a novel metoprolol tartrate-containing matrix sustained-release tablet, i.e. a metoprolol tartrate matrix sustained-release tablet with a regulation layer. The novel double-layer matrix sustained-release tablet with the regulation layer is prepared by adding the regulation layer on the basis of the traditional metoprolol tartrate matrix sustained-release tablet, can release medicines uniformly in 24 hours, overcomes the defects of the metoprolol tartrate sustained-release tablet in the prior art, and has the advantages of ideal release effect, simple process and low cost.

The invention belongs to the field of medicinal preparation and discloses a metoprolol tartrate sustained release pellet and a preparation method thereof. The pellet is prepared by the following steps: preparing a parent kernel and a pellet core by using a centrifugal granulation method and spraying a sustained release coat on the pellet by using a fluidized bed coating method; and the method specifically comprises the following steps: (a) preparation of the parent kernel: taking metoprolol tartrate fine powder; adding the metoprolol tartrate fine powder into a pellet processing machine; spraying a wetting agent into the fine powder so as to form a certain number of parent kernels; and screening the parent kernels by using a screening method; (b) preparation of the pellet core: taking the parent kernels; adding the parent kernels into the pellet processing machine; spraying a wetting agent so that the surfaces of the parent kernels are wet; meanwhile, feeding the metoprolol tartrate fine powder into the pellet processing machine so that the parent kernels are laminated to be grown to pellet cores; and screening the pellet cores by using a screening method so as to obtain target pellet cores; and (c) coating of the pellet cores: taking the pellet cores; adding the pellet cores into a fluidized bed; and spraying sustained release coats on the pellet cores by using the fluidized bed coating method. The metoprolol tartrate sustained release pellet disclosed by the invention has the advantages of high true sphericity, small particle size, uniform particle size distribution, low production cost and medicine content of 100% in the pellet core.